- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01077284
Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones
A Multicenter, Randomized, Double-Blind, Placebo and Allopurinol Controlled, Phase 2 Study to Evaluate Febuxostat in the Medical Management of Subjects With Hyperuricosuria and Calcium Oxalate Stones
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Nephrolithiasis, also called kidney stone disease, occurs in patients with genetic susceptibility and who may have a broad spectrum of metabolic disorders and other comorbid conditions (for example obesity or diabetes). These renal stones develop as a result of supersaturation. Calcium oxalate (CaOx) is the most common type of stone. Reducing the urinary excretion of uric acid is an established approach for the treatment of CaOx kidney stones.
The objective of this study is to evaluate treatment with febuxostat compared to allopurinol or placebo in the reduction of 24-hour urine uric acid (uUA) excretion levels in hyperuricosuric patients with a recent history of renal stones and the presence of at least one CaOx stone larger than or equal to 3 mm as seen on Multidetector Computed Tomographic Angiography (MDCT).
Participants in this study will be required to make 4 office visits provide 3 urine samples and undergo 2 MDCT scans (a type of x-ray) of their kidneys.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States
-
-
Alaska
-
Anchorage, Alaska, United States
-
-
Arizona
-
Tucson, Arizona, United States
-
-
California
-
Costa Mesa, California, United States
-
Orange, California, United States
-
Palmdale, California, United States
-
Poway, California, United States
-
Rancho Cucamonga, California, United States
-
San Diego, California, United States
-
Santa Ana, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
-
Connecticut
-
New Britain, Connecticut, United States
-
-
Florida
-
Miami, Florida, United States
-
-
Georgia
-
Augusta, Georgia, United States
-
-
Hawaii
-
Honolulu, Hawaii, United States
-
-
Idaho
-
Boise, Idaho, United States
-
Meridian, Idaho, United States
-
-
Kentucky
-
Lexington, Kentucky, United States
-
-
Michigan
-
Kalamazoo, Michigan, United States
-
-
Mississippi
-
Jackson, Mississippi, United States
-
-
New Mexico
-
Albuquerque, New Mexico, United States
-
-
New York
-
New Windsor, New York, United States
-
-
North Carolina
-
Shelby, North Carolina, United States
-
Wilmington, North Carolina, United States
-
-
Rhode Island
-
East Providence, Rhode Island, United States
-
-
Texas
-
Dallas, Texas, United States
-
Houston, Texas, United States
-
Sugar Land, Texas, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has hyperuricosuria, defined as a daily urine uric acid excretion greater than 700 mg as measured by 24-hour urine collection prior to randomization.
- Has at least one calcium oxalate stone greater than or equal to 3 mm in its longest in-plane diameter, identified by Multiple Detector Computated Tomography prior to randomization.
- Has a recent (within the previous 5 years) history of renal stones prior to screening.
Exclusion Criteria:
- Has gout, secondary hyperuricemia or has experienced a gout flare.
- Has a history of xanthinuria.
- Has received allopurinol or probenecid within 2 years prior to randomization.
- Has received febuxostat.
- Has alanine aminotransferase and/or aspartate aminotransferase values greater than 2.0 times the upper limit of normal at the Screening Visit.
- Has an abnormal serum calcium level at the Screening Visit.
- Has a significant medical condition and/or conditions that would interfere with the treatment, safety or compliance with the protocol according to the judgment of the Investigator.
- Has a history of drug abuse or a history of alcohol abuse within 5 years prior to the Screening Visit.
- Participant's measured creatinine clearance is less than 30 mL/min at the Screening Visit.
Has hypercalciuria at Screening, while on a regular unrestricted diet, defined as urinary excretion of:
- greater than 250 mg of calcium/24-hour for females of body weight less than 62.5 kg; OR
- greater than 300 mg calcium/24-hour for males of body weight less than 75 kg; OR
- greater than 4 mg calcium/kg/24-hour for males of body weight greater than or equal 75 kg and females of body weight greater than or equal 62.5 kg.
EXCLUDED MEDICATIONS:
- Febuxostat, allopurinol, probenecid.
- Salicylates (chronic use of aspirin ≤325 mg/day is allowed).
- Azathioprine.
- Mercaptopurine.
- Theophylline.
- Colchicine.
- Pyrazinamide.
- Sulfamethoxazole/trimethoprim.
- Losartan.
The following restrictions also apply during the study:
- Long-term use (more than 4 continuous weeks) of prescription or over-the-counter nonsterioidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors.
- If receiving diuretics, participant must have been on a stable dose for at least 30 days prior to screening. No changes in dosage are allowed during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Febuxostat
Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
|
Febuxostat capsules
Other Names:
|
Active Comparator: Allopurinol
Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.
|
Allopurinol capsules
Other Names:
|
Placebo Comparator: Placebo
Placebo-matching capsules, orally, once daily for up to 6 months.
|
Placebo-matching capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline to Month 6 in 24-hour Urine Uric Acid (uUA) Excretion
Time Frame: Baseline and Month 6
|
The change from Baseline to Month 6 in 24-hour urine uric acid is expressed as a percentage of the Baseline uUA value.
|
Baseline and Month 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline to Month 6 in the In-plane Diameter of the Largest Calcium Oxalate (CaOx) Stone
Time Frame: Baseline and Month 6
|
Multidetector Computed Tomography (MDCT) was used to visualize and measure calcium oxalate kidney stones at Baseline and after 6 months of treatment.
All MDCT images were analyzed independently by a Central Reader.
The change from Baseline to month 6 is expressed as a percentage of the Baseline largest in-plane diameter.
|
Baseline and Month 6
|
Change From Baseline to Month 6 in the Number of Calcium Oxalate Stones
Time Frame: Baseline and Month 6
|
Multidetector Computed Tomography (MDCT) was used to visualize and count calcium oxalate kidney stones at Baseline and after 6 months of treatment.
All MDCT images were analyzed independently by a Central Reader.
|
Baseline and Month 6
|
Change From Baseline to Month 6 in 24-hour Measured Creatinine Clearance
Time Frame: Baseline and Month 6
|
Creatinine clearance is a measure of how well the kidneys are filtering creatinine, a waste product produced by the muscles.
Measured creatinine clearance was calculated according to the following: Urine 24 hour Creatinine/Serum Creatinine x (total Urine volume/elapsed time) x (1.73/body surface area).
|
Baseline and Month 6
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Pathological Conditions, Anatomical
- Urolithiasis
- Urinary Calculi
- Calculi
- Kidney Calculi
- Nephrolithiasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites
- Protective Agents
- Antioxidants
- Free Radical Scavengers
- Gout Suppressants
- Allopurinol
- Febuxostat
Other Study ID Numbers
- TMX-67_201
- U1111-1113-6322 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Stones
-
Indiana Kidney Stone InstituteUniversity of Washington; VA Puget Sound Health Care SystemCompleted
-
Omeros CorporationCompletedUrinary Calculi | Renal Calculi | Kidney Stones | Urinary Stones | Urinary Tract StonesUnited States
-
Mayo ClinicCompletedKidney Calculi | Nephrolithiasis | Kidney Stones | Renal StonesUnited States, Canada
-
United States Naval Medical Center, San DiegoUnknown
-
University of British ColumbiaPercutaneous Systems, Inc.Completed
-
Robert SworWilliam Beaumont HospitalsCompletedKidney Stones | Ureteral StonesUnited States
-
Mansoura UniversityUnknownUrologic Diseases | Stones, Kidney | Stone, Urinary | Shock Wave LithotripsyEgypt
-
Mansoura UniversityRecruitingUrinary Stones | Renal StoneEgypt
-
Services Hospital, LahoreCompleted
-
Adva-TecUniversity of British ColumbiaCompletedUnilateral Ureteral Stone | Renal Stone Fragments ≤ 2mmCanada
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States